Pancreatic Cancer Research

ResearcherKunming Medical UniversityActive in the last 2 years

Bo Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3568-6925; OpenAlex author ID A5085619108. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 3 papers

Papers 8

  1. METTL3 and METTL14 drive pancreatic adenocarcinoma progression via m6A-dependent alternative splicing in PANC-1 cells. Co-author DOI 10.1007/s12672-025-03393-3↗
  2. O-GlcNAcylation with ubiquitination stabilizes METTL3 to promoting HMGB1 degradation to inhibit ferroptosis and enhance gemcitabine resistance in pancreatic ca… Co-author DOI 10.1186/s10020-025-01285-4↗
  3. miR-145-5p modulates CDCA3 to overcome gemcitabine resistance in pancreatic cancer. Co-author DOI 10.4149/gpb_2024047↗
  4. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. Co-author DOI 10.1002/advs.202206335↗
  5. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  6. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF. Last author DOI 10.20892/j.issn.2095-3941.2022.0299↗
  7. Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis. Co-author DOI 10.1177/1559325820942065↗
  8. Downregulation of CDCA3 expression inhibits tumor formation in pancreatic cancer. Co-author DOI 10.4149/neo_2020_200411n388↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renchao Zou · 4 shared papers, 2020–2025 · strength 0.87
  2. Dongyun Cun · 2 shared papers, 2025 · strength 0.49
  3. Dong Wei · 2 shared papers, 2025 · strength 0.49
  4. Tao Wu · 2 shared papers, 2025 · strength 0.49
  5. Jiayun Ge · 2 shared papers, 2020–2025 · strength 0.38
  6. Chongbiao Huang · 2 shared papers, 2023 · strength 0.28
  7. Jihui Hao · 2 shared papers, 2023 · strength 0.28
  8. Zhihong Zhang · 1 shared paper, 2025 · strength 0.27
  9. Xin Wang · 1 shared paper, 2025 · strength 0.27
  10. Qiuhong Wang · 1 shared paper, 2025 · strength 0.26
  11. Qiuhong Wang · 1 shared paper, 2025 · strength 0.24
  12. Hongquan Wang · 1 shared paper, 2022 · strength 0.22
  13. Yan Wang · 1 shared paper, 2022 · strength 0.22
  14. Chao Wu · 1 shared paper, 2023 · strength 0.14
  15. Shengnan Li · 1 shared paper, 2023 · strength 0.14
  16. Peng Xie · 1 shared paper, 2023 · strength 0.14
  17. Weishuai Liu · 1 shared paper, 2023 · strength 0.14
  18. Xiaozhou Yu · 1 shared paper, 2023 · strength 0.14
  19. Shengyu Yang · 1 shared paper, 2023 · strength 0.14
  20. Danqi Fu · 1 shared paper, 2023 · strength 0.14
  21. Jinsheng Ding · 1 shared paper, 2023 · strength 0.14
  22. Xiuchao Wang · 1 shared paper, 2023 · strength 0.14
  23. Song Gao · 1 shared paper, 2023 · strength 0.14
  24. Chuntao Gao · 1 shared paper, 2023 · strength 0.14
  25. Tiansuo Zhao · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.